| Autor: |
Tursi, Antonio, Franceschi, Marilisa, Allegretta, Leonardo, Savarino, Edoardo, De Bastiani, Rudi, Elisei, Walter, Baldassarre, Gianluca, Ferronato, Antonio, Scida, Serena, Miraglia, Chiara, Penna, Antonio, Licci, Claudio, Rizzo, Giovanni Luca, Pranzo, Giuseppe, Cassieri, Claudio, Brandimarte, Giovanni, Picchio, Marcello, Di Mario, Francesco |
| Předmět: |
|
| Zdroj: |
Digestive Diseases; Jul2018, Vol. 36 Issue 4, p264-268, 5p, 3 Charts |
| Abstrakt: |
Background: Our aims were to assess the real life effectiveness and safety of the new bismuth-containing quadruple therapy in a large population of patients infected by Helicobacter pylori. Methods: Consecutive dyspeptic H. pylori-positive patients were enrolled, both naïve for treatment and already unsuccessfully treated. Patients were treated with Pylera® 3 capsules 4 times/daily plus omeprazole 20 mg or esomeprazole 40 mg 2 times/daily for 10 days. Eradication was confirmed using a urea-breath test (at least 30 days after the end of the treatment). Efficacy and safety were assessed. Results: A total of 349 patients were treated. H. pylori eradication was achieved in 316 (90.5%, 95% CIs 80.8–1.0) patients in the intention-to-treat population, and in 93.5% (95% CIs 83.5–1.0) in the per-protocol population. No difference in the eradication rate was found between naïve and previously treated patients (91.3 vs. 90.0%, p = 0.901). Adverse events occurred in 55 patients (15.8%, 95% CIs 11.9–20.1). Five patients discontinued treatment: 2 patients suffered from severe abdominal pain, one patient from headache, one patient from diarrhea, and one patient from diffuse urticarial rush. Conclusions: Pylera® achieved a remarkable eradication rate in real life both as first treatment and as a rescue therapy, with a good safety profile. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
